ARS Pharmaceuticals Secures Major Formulary Wins, Strengthens Market Position for Neffy

TipRanksFeb 21 05:35 ET

William Blair Initiates ARS Pharmaceuticals(SPRY.US) With Buy Rating

Moomoo NewsFeb 21 05:34 ET · Ratings

Express News | ARS Pharmaceuticals Announces Optumrx, Cigna Healthcare and Navitus Health Systems Add Neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

ReutersFeb 20 19:02 ET

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add Neffy (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

GlobeNewswireFeb 20 19:02 ET

ARS Pharmaceuticals to Showcase Innovation and Present Data on Neffy (Epinephrine Nasal Spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

GlobeNewswireFeb 18 08:00 ET

Oppenheimer Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $40

Moomoo NewsFeb 10 08:31 ET · Ratings